Oscar Health (OSCR) stock is pushing higher on Wednesday after Barclays’ senior analyst Andrew Mok issued a bullish note in favor of the health insurance company.
In his research note, Mok upgraded OSCR to “Overweight” and raised his price objective to $35, indicating potential for another 25% rally from current levels.